CM-4307

Generic Name: CM-4307

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₆ClF_₃N_₄O_₃

CAS Number: 1130115-44-4

Unique Ingredient Identifier: 41XGO0VS1U

Background: CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

Indication: 用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。

Clinical Trials

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Phase 2

Recruiting

Conditions: Biliary Malignant Tumors

Interventions: Drug: Donafenib
Drug: capecitabine

First Posted Date: 2024-11-12

Last Posted Date: 2025-01-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 70

Registration Number: NCT06685289

Locations: 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma with PVTT

Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)
Drug: Donafenib

First Posted Date: 2024-10-17

Last Posted Date: 2024-10-17

Lead Sponsor: Fei Gao

Target Recruit Count: 40

Registration Number: NCT06646198

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Not Applicable

Recruiting

Conditions: Hepatocellular Carcinoma
Microwave Ablation
Donafenib
Recurrent Tumor

Interventions: Procedure: Thermal ablation
Drug: Donafenib

First Posted Date: 2024-09-24

Last Posted Date: 2024-12-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 108

Registration Number: NCT06609876

Locations: 🇨🇳
Chinese PLA General hospital, Beijing, None Selected, China

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Not Applicable

Recruiting

Conditions: Hepatocellular Carcinoma
Adjuvant Therapy

Interventions: Drug: Donafenib

First Posted Date: 2024-09-03

Last Posted Date: 2024-09-03

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 204

Registration Number: NCT06581315

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Drug: Sintilimab
Other: HAIC

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06512467

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib + Envafolimab

First Posted Date: 2024-07-12

Last Posted Date: 2024-07-12

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 45

Registration Number: NCT06498622

Locations: 🇨🇳
No.2 People's Hospital of Fuyang city, Fuyang, Anhui, China
🇨🇳
Anhui province hospital, Hefei, Anhui, China

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

Phase 4

Not yet recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Procedure: transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy
Drug: PD-1,PD-L1

First Posted Date: 2024-07-11

Last Posted Date: 2024-07-11

Lead Sponsor: Tongji Hospital

Target Recruit Count: 32

Registration Number: NCT06496815

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Thyroid Gland Carcinoma

Interventions: Drug: Anlotinib
Drug: Lenvatinib
Drug: Sorafenib
Drug: Donafenib
Drug: Everolimus
Drug: Apatinib
Drug: Dabrafenib + Trametinib
Drug: Cabozantinib
Drug: Vandetanib
Drug: Entrectinib
Drug: Pralsetinib
Drug: Larotrectinib

First Posted Date: 2024-07-01

Last Posted Date: 2024-12-05

Lead Sponsor: West China Hospital

Target Recruit Count: 75

Registration Number: NCT06482086

Locations: 🇨🇳
West China hospital, Chengdu, Sichuan, China

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: ZG005 Powder for Injection
Drug: Donafenib Tosilate Tablets

First Posted Date: 2024-02-02

Last Posted Date: 2024-06-14

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 130

Registration Number: NCT06239298

Locations: 🇨🇳
The Second Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Not Applicable

Not yet recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Biological: ZG005 Powder for Injection
Biological: Bevacizumab
Drug: Donafenib Tosilate Tablets

First Posted Date: 2024-01-31

Last Posted Date: 2024-01-31

Lead Sponsor: Changsha Taihe Hospital

Target Recruit Count: 30

Registration Number: NCT06233994

Locations: 🇨🇳
Changsha Taihe Hospital, Changsha, Hunan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy